Advertisement

April 28, 2020

Terumo's Biodegradable Drug-Eluting BioPearl Microspheres Receive CE Mark Approval

April 28, 2020—Terumo Europe NV announced that the company's BioPearl microspheres has received European CE Mark approval as an option for patients eligible for locoregional embolization of target artery blood supply to liver cancer. The next-generation drug-eluting BioPearl microspheres are designed to preserve target artery access after transarterial chemoembolization (TACE), opening up the potential for cyclic treatment. BioPearl microspheres have been designed to have controlled drug elution while keeping future treatment options open, stated the company.

"The availability of BioPearl microspheres is an important milestone in interventional oncology as it is the first biodegradable drug-eluting microsphere loadable with three chemotherapeutic drugs (doxorubicin, idarubicinm, and epirubicin)," commented Peter Coenen in the company's press release. Mr. Coenen is President of Interventional Systems Terumo EMEA covering Europe, the Middle East and Africa. 

Also in Terumo Europe's announcement, Professor Thierry De Baere, MD, from Institute Gustave Roussy in Villejuif, France, stated, "Interventional oncology is not a stand-alone specialty, and by working with medical oncologists, we will be able to optimize current and future treatments, namely by delivering drugs directly into the tumor. Through such collaboration, we may be able to reduce the dosage and improve the toxicity profile of anticancer drugs and ultimately improve the field. BioPearl drug-eluting microspheres and its degradation profile is a significant next step toward enhancing localized drug delivery and hopefully improving patient outcomes."

Advertisement


April 29, 2020

Terumo Aortic’s Thoraflex Hybrid Device Granted FDA Breakthrough Device Designation

April 28, 2020

IceCure Continues Global Expansion of ProSense Cryoablation System With Approval in India